Human CD8


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
05 2019
Historique:
received: 13 08 2018
accepted: 10 01 2019
pubmed: 20 2 2019
medline: 30 4 2019
entrez: 20 2 2019
Statut: ppublish

Résumé

Influenza A, B and C viruses (IAV, IBV and ICV, respectively) circulate globally and infect humans, with IAV and IBV causing the most severe disease. CD8

Identifiants

pubmed: 30778243
doi: 10.1038/s41590-019-0320-6
pii: 10.1038/s41590-019-0320-6
doi:

Substances chimiques

Epitopes, T-Lymphocyte 0
Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

613-625

Références

Krammer, F. et al. Influenza. Nat. Rev. Dis. Primers 4, 3 (2018).
doi: 10.1038/s41572-018-0002-y
Nussing, S. et al. Innate and adaptive T cells in influenza disease. Front. Med. 12, 34–47 (2018).
doi: 10.1007/s11684-017-0606-8
Paules, C. & Subbarao, K. Influenza. Lancet 390, 697–708 (2017).
doi: 10.1016/S0140-6736(17)30129-0
Koutsakos, M., Nguyen, T. H., Barclay, W. S. & Kedzierska, K. Knowns and unknowns of influenza B viruses. Future Microbiol. 11, 119–135 (2016).
doi: 10.2217/fmb.15.120
Matsuzaki, Y. et al. Clinical features of influenza C virus infection in children. J. Infect. Dis. 193, 1229–1235 (2006).
doi: 10.1086/502973
Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417–429 e410 (2018).
doi: 10.1016/j.cell.2018.03.030
Corti, D. et al. Tackling influenza with broadly neutralizing antibodies. Curr. Opin. Virol. 24, 60–69 (2017).
doi: 10.1016/j.coviro.2017.03.002
Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343–1348 (2012).
doi: 10.1126/science.1222908
Hayward, A. C. et al. Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the Flu Watch Cohort Study. Am. J. Respir. Crit. Care. Med. 191, 1422–1431 (2015).
doi: 10.1164/rccm.201411-1988OC
McMichael, A. J., Gotch, F. M., Noble, G. R. & Beare, P. A. Cytotoxic T-cell immunity to influenza. New Engl. J. Med. 309, 13–17 (1983).
doi: 10.1056/NEJM198307073090103
van de Sandt, C. E. et al. Influenza B virus-specific CD8+T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage. J. Gen. Virol. 96, 2061–2073 (2015).
doi: 10.1099/vir.0.000156
Gras, S. et al. Cross-reactive CD8+T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc. Natl Acad. Sci. USA 107, 12599–12604 (2010).
doi: 10.1073/pnas.1007270107
Greenbaum, J. A. et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc. Natl Acad. Sci. USA 106, 20365–20370 (2009).
doi: 10.1073/pnas.0911580106
Quinones-Parra, S. M. et al. A role of influenza virus exposure history in determining pandemic susceptibility and CD8+ T cell responses. J. Virol. 90, 6936–6947 (2016).
doi: 10.1128/JVI.00349-16
Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305–1312 (2013).
doi: 10.1038/nm.3350
Quinones-Parra, S. et al. Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc. Natl Acad. Sci. USA 111, 1049–1054 (2014).
doi: 10.1073/pnas.1322229111
Wang, Z. et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells. Nat. Commun. 6, 6833 (2015).
doi: 10.1038/ncomms7833
Wang, Z. et al. Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during fatal H7N9 disease. Nat. Commun. 9, 824 (2018).
doi: 10.1038/s41467-018-03243-7
Koutsakos, M. et al. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Sci. Transl. Med. 10, eaan8405 (2018).
doi: 10.1126/scitranslmed.aan8405
Ramarathinam, S. H. et al. Identification of native and posttranslationally modified HLA-B*57:01-restricted HIV envelope derived epitopes using immunoproteomics. Proteomics 18, e1700253 (2018).
doi: 10.1002/pmic.201700253
Williamson, N. A. & Purcell, A. W. Use of proteomics to define targets of T-cell immunity. Expert. Rev. Proteomics 2, 367–380 (2005).
doi: 10.1586/14789450.2.3.367
Alexander, J. et al. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Hum. Immunol. 71, 468–474 (2010).
doi: 10.1016/j.humimm.2010.02.014
Rosendahl Huber, S. K. et al. Chemical modification of influenza CD8+ T-cell epitopes enhances their immunogenicity regardless of immunodominance. PLoS ONE 11, e0156462 (2016).
doi: 10.1371/journal.pone.0156462
Terajima, M., Babon, J. A., Co, M. D. & Ennis, F. A. Cross-reactive human B cell and T cell epitopes between influenza A and B viruses. Virol. J. 10, 244 (2013).
doi: 10.1186/1743-422X-10-244
Zemmour, J., Little, A. M., Schendel, D. J. & Parham, P. The HLA-A,B “negative” mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J. Immunol. 148, 1941–1948 (1992).
pubmed: 1541831
Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H. G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290–296 (1991).
doi: 10.1038/351290a0
Alanio, C., Lemaitre, F., Law, H. K., Hasan, M. & Albert, M. L. Enumeration of human antigen-specific naive CD8+T cells reveals conserved precursor frequencies. Blood 115, 3718–3725 (2010).
doi: 10.1182/blood-2009-10-251124
Moon, J. J. et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27, 203–213 (2007).
doi: 10.1016/j.immuni.2007.07.007
Nguyen, T. H. O. et al. Perturbed CD8(+) T cell immunity across universal influenza epitopes in the elderly. J. Leukoc. Biol. 103, 321–339 (2018).
pubmed: 28928269
Chandele, A. et al. Characterization of human CD8 T Cell responses in Dengue virus-infected patients from India. J. Virol. 90, 11259–11278 (2016).
doi: 10.1128/JVI.01424-16
Jozwik, A. et al. RSV-specific airway resident memory CD8+T cells and differential disease severity after experimental human infection. Nat. Commun. 6, 10224 (2015).
doi: 10.1038/ncomms10224
Miller, J. D. et al. Human effector and memory CD8+T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710–722 (2008).
doi: 10.1016/j.immuni.2008.02.020
Hillaire, M. L. et al. Characterization of the human CD8(+) T cell response following infection with 2009 pandemic influenza H1N1 virus. J. Virol. 85, 12057–12061 (2011).
doi: 10.1128/JVI.05204-11
de Bree, G. J. et al. Selective accumulation of differentiated CD8+T cells specific for respiratory viruses in the human lung. J. Exp. Med. 202, 1433–1442 (2005).
doi: 10.1084/jem.20051365
Piet, B. et al. CD8(+) T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J. Clin. Invest. 121, 2254–2263 (2011).
doi: 10.1172/JCI44675
Sathaliyawala, T. et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 38, 187–197 (2013).
doi: 10.1016/j.immuni.2012.09.020
Allen, R. J., Koutsakos, M., Hurt, A. C. & Kedzierska, K. Uncomplicated cystitis in an adult male following influenza B virus infection. Am. J. Case Rep. 18, 190–193 (2017).
doi: 10.12659/AJCR.902172
Valkenburg, S. A. et al. Molecular basis for universal HLA-A*0201-restricted CD8+T-cell immunity against influenza viruses. Proc. Natl Acad. Sci. USA 113, 4440–4445 (2016).
doi: 10.1073/pnas.1603106113
Pascolo, S. et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 185, 2043–2051 (1997).
doi: 10.1084/jem.185.12.2043
Nguyen, T. H. et al. Understanding CD8(+) T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope. Clin. Transl. Immunology 6, e134 (2017).
doi: 10.1038/cti.2017.4
Epstein, S. L., Lo, C. Y., Misplon, J. A. & Bennink, J. R. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J. Immunol. 160, 322–327 (1998).
pubmed: 9551987
Babon, J. A., Cruz, J., Ennis, F. A., Yin, L. & Terajima, M. A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus. J. Virol. 86, 9233–9243 (2012).
doi: 10.1128/JVI.06325-11
Pedersen, S. R. et al. Immunogenicity of HLA class I and II double restricted influenza A-derived peptides. PLoS ONE 11, e0145629 (2016).
doi: 10.1371/journal.pone.0145629
Tan, A. C. et al. The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol. Cell Biol. 91, 96–104 (2013).
doi: 10.1038/icb.2012.54
Wang, L. et al. Functional genomics reveals linkers critical for influenza virus polymerase. J. Virol. 90, 2938–2947 (2015).
doi: 10.1128/JVI.02400-15
Fulton, B. O., Sun, W., Heaton, N. S. & Palese, P. The influenza B virus hemagglutinin head domain is less tolerant to transposon mutagenesis than that of the influenza A virus. J. Virol. 92, e00754-18 (2018).
Allen, E. K. et al. SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans. Nat. Med. 23, 975–983 (2017).
doi: 10.1038/nm.4370
Oshansky, C. M. et al. Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load. Am. J. Respir. Crit. Care. Med. 189, 449–462 (2014).
doi: 10.1164/rccm.201309-1616OC
Bird, N. L. et al. Oseltamivir prophylaxis reduces inflammation and facilitates establishment of cross-strain protective T cell memory to influenza viruses. PLoS ONE 10, e0129768 (2015).
doi: 10.1371/journal.pone.0129768
Valkenburg, S. A. et al. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold. PLoS Pathog. 6, e1001039 (2010).
doi: 10.1371/journal.ppat.1001039
Bao, Y. et al. The influenza virus resource at the National Center for Biotechnology Information. J. Virol. 82, 596–601 (2008).
doi: 10.1128/JVI.02005-07
Nguyen, T. H. et al. Maintenance of the EBV-specific CD8(+) TCRalphabeta repertoire in immunosuppressed lung transplant recipients. Immunol. Cell Biol. 95, 77–86 (2017).
doi: 10.1038/icb.2016.71
Dudek, N. L. et al. Constitutive and inflammatory immunopeptidome of pancreatic beta-cells. Diabetes 61, 3018–3025 (2012).
doi: 10.2337/db11-1333
Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32, 511–517 (2016).
doi: 10.1093/bioinformatics/btv639
Lundegaard, C. et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36, W509–W512 (2008).
doi: 10.1093/nar/gkn202
Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007–1017 (2003).
doi: 10.1110/ps.0239403
Colaert, N., Helsens, K., Martens, L., Vandekerckhove, J. & Gevaert, K. Improved visualization of protein consensus sequences by iceLogo. Nat. Methods 6, 786–787 (2009).
doi: 10.1038/nmeth1109-786
Eltahla, A. A. et al. Linking the T cell receptor to the single cell transcriptome in antigen-specific human T cells. Immunol. Cell Biol. 94, 604–611 (2016).
doi: 10.1038/icb.2016.16
Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc. 9, 171–181 (2014).
doi: 10.1038/nprot.2014.006

Auteurs

Marios Koutsakos (M)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Patricia T Illing (PT)

Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Thi H O Nguyen (THO)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Nicole A Mifsud (NA)

Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Jeremy Chase Crawford (JC)

Department of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.

Simone Rizzetto (S)

School of Medical Sciences and The Kirby Institute, UNSW, Sydney, New South Wales, Australia.

Auda A Eltahla (AA)

School of Medical Sciences and The Kirby Institute, UNSW, Sydney, New South Wales, Australia.

E Bridie Clemens (EB)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Sneha Sant (S)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Brendon Y Chua (BY)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Chinn Yi Wong (CY)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

E Kaitlynn Allen (EK)

Department of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.

Don Teng (D)

Infection and Immunity Program & Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Pradyot Dash (P)

Department of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.

David F Boyd (DF)

Department of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.

Ludivine Grzelak (L)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Biology Department, École Normale Supérieure Paris-Saclay, Université Paris-Saclay, Cachan, France.

Weiguang Zeng (W)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Aeron C Hurt (AC)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Ian Barr (I)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
School of Applied Biomedical Sciences, Federation University, Churchill, Victoria, Australia.

Steve Rockman (S)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Seqirus, Parkville, Victoria, Australia.

David C Jackson (DC)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Tom C Kotsimbos (TC)

Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.
Department of Medicine, Monash University, Central Clinical School, The Alfred Hospital, Melbourne, Victoria, Australia.

Allen C Cheng (AC)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, Victoria, Australia.

Michael Richards (M)

Victorian Infectious Diseases Service, The Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Glen P Westall (GP)

Lung Transplant Unit, Alfred Hospital, Melbourne, Victoria, Australia.

Thomas Loudovaris (T)

Immunology and Diabetes Unit, St Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.

Stuart I Mannering (SI)

Lung Transplant Unit, Alfred Hospital, Melbourne, Victoria, Australia.

Michael Elliott (M)

Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Chris O'Brien Lifehouse Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Stuart G Tangye (SG)

Immunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

Linda M Wakim (LM)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Jamie Rossjohn (J)

Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.
Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, UK.

Dhanasekaran Vijaykrishna (D)

Infection and Immunity Program & Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Fabio Luciani (F)

School of Medical Sciences and The Kirby Institute, UNSW, Sydney, New South Wales, Australia.

Paul G Thomas (PG)

Department of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.

Stephanie Gras (S)

Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.

Anthony W Purcell (AW)

Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Katherine Kedzierska (K)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia. kkedz@unimelb.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH